Topics:

All Content

ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.

Monitoring minimal residual disease and real-time quantitative polymerase chain reaction can predict relapse in pediatric acute lymphoblastic leukemia patients.

A 63-year-old man presents with pain in the right arm. A lesion in the humerus is identified and a biopsy is taken. What is your diagnosis?

Adopting a combination of five healthy behaviors is linked to a reduction in the risk of developing colorectal cancer, according to the results of a study.

In the field of oncology, we are fortunate to possess a vast and ever-expanding trove of knowledge, and we now have a sufficient foundation of knowledge in many cancers to afford ourselves the luxury of striving to seek wisdom as well.

A recent study has confirmed that TERT promoter mutations are common genetic mutations in cutaneous melanoma, mutations that may be linked with poor prognosis.

A phase III trial of vosaroxin failed to meet its primary overall survival endpoint in patients with first relapsed or refractory acute myeloid leukemia.

Aggressive variants of prostate cancer often take the form of neuroendocrine or small-cell carcinomas, which frequently lack androgen receptor expression and respond poorly to hormonal therapies.

Treatment-emergent small-cell/neuroendocrine prostate cancer is likely to become of increasing clinical relevance in the era of widespread use of potent androgen receptor–targeted therapies.

Ultimately, while further follow-up will be enlightening, we believe that there is sufficient evidence now from the primary analysis of CHAARTED to justify the combination of docetaxel and androgen deprivation therapy in all men with metastatic hormone-sensitive prostate cancer.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.